MA56469A - Anticorps de liaison à psma avec une affinité réduite pour le récepteur fc néonatal - Google Patents

Anticorps de liaison à psma avec une affinité réduite pour le récepteur fc néonatal

Info

Publication number
MA56469A
MA56469A MA056469A MA56469A MA56469A MA 56469 A MA56469 A MA 56469A MA 056469 A MA056469 A MA 056469A MA 56469 A MA56469 A MA 56469A MA 56469 A MA56469 A MA 56469A
Authority
MA
Morocco
Prior art keywords
psma
neonatal
receptor
binding antibodies
reduced affinity
Prior art date
Application number
MA056469A
Other languages
English (en)
Inventor
Christian Peter Behrenbruch
Michael Paul Wheatcroft
Original Assignee
Telix Int Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2019902344A external-priority patent/AU2019902344A0/en
Application filed by Telix Int Pty Ltd filed Critical Telix Int Pty Ltd
Publication of MA56469A publication Critical patent/MA56469A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1072—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1075—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/534—Production of labelled immunochemicals with radioactive label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1084—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
    • A61K51/1087—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin the immunoglobulin comprises domains from different animal species, e.g. chimeric immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/528—CH4 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Optics & Photonics (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
MA056469A 2019-07-02 2020-07-02 Anticorps de liaison à psma avec une affinité réduite pour le récepteur fc néonatal MA56469A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AU2019902344A AU2019902344A0 (en) 2019-07-02 Antibodies

Publications (1)

Publication Number Publication Date
MA56469A true MA56469A (fr) 2022-05-11

Family

ID=74100117

Family Applications (1)

Application Number Title Priority Date Filing Date
MA056469A MA56469A (fr) 2019-07-02 2020-07-02 Anticorps de liaison à psma avec une affinité réduite pour le récepteur fc néonatal

Country Status (13)

Country Link
US (1) US20220323619A1 (fr)
EP (1) EP3994177A4 (fr)
JP (2) JP7678769B2 (fr)
KR (1) KR20220057517A (fr)
CN (1) CN114555641A (fr)
AU (1) AU2020299025A1 (fr)
BR (1) BR112021026663A2 (fr)
CA (1) CA3141471A1 (fr)
CL (1) CL2021003563A1 (fr)
IL (1) IL289523A (fr)
MA (1) MA56469A (fr)
MX (1) MX2021015669A (fr)
WO (1) WO2021000018A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12350686B2 (en) * 2011-11-21 2025-07-08 Pneumatic Scale Corporation Centrifuge system for separating cells in suspension
US11878311B2 (en) * 2011-11-21 2024-01-23 Pneumatic Scale Corporation Centrifuge system for separating cells in suspension
US11957998B2 (en) * 2019-06-06 2024-04-16 Pneumatic Scale Corporation Centrifuge system for separating cells in suspension
MX2023009761A (es) * 2021-02-22 2023-11-14 Abdera Therapeutics Inc Inmunoconjugados para terapia dirigida con radioisotopos.
US20240359144A1 (en) * 2021-09-01 2024-10-31 Telix Pharmaceuticals (Innovations) Pty Ltd Aggregate separation method
CN119173283A (zh) 2022-05-17 2024-12-20 拜耳股份有限公司 靶向前列腺特异性膜抗原的放射性药物络合物及其组合
EP4279092A1 (fr) 2022-05-17 2023-11-22 Bayer AG Complexes radiopharmaceutiques
IL319125A (en) 2022-08-22 2025-04-01 Abdera Therapeutics Inc DLL3 binding molecules and their uses
AU2024233129A1 (en) * 2023-03-09 2025-09-18 Telix Pharmaceuticals (Innovations) Pty Ltd Multifunctional antibodies
AU2023439766A1 (en) * 2023-04-04 2025-09-11 Eli Lilly And Company Methods of treating cancers expressing pdgfralpha
WO2024207070A1 (fr) * 2023-04-04 2024-10-10 Telix Pharmaceuticals (Innovations) Pty Ltd Méthodes de traitement de cancers exprimant pdgfralpha
WO2024207069A1 (fr) * 2023-04-04 2024-10-10 Telix Pharmaceuticals (Innovations) Pty Ltd Réactifs et procédés d'imagerie de cancers exprimant pdgfralpha
WO2025184427A1 (fr) * 2024-02-27 2025-09-04 Osteologic Therapeutics, Inc. Anticorps ciblant les os et leurs méthodes d'utilisation

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US8466263B2 (en) * 2005-12-02 2013-06-18 Dana-Farber Cancer Institute, Inc. Carbonic anhydrase IX (G250) anitbodies
SG176947A1 (en) * 2009-07-03 2012-01-30 Avipep Pty Ltd Immuno-conjugates and methods for producing them
EP2506876B1 (fr) * 2009-12-02 2016-10-12 Imaginab, Inc. Minobodies j591 et cys-diabodies pour le ciblage de l'antigène membranaire spécifique de la prostate humaine (psma), et procédés d'utilisation
TW201817745A (zh) * 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
US9492563B2 (en) * 2012-10-30 2016-11-15 Esperance Pharmaceuticals, Inc. Antibody/drug conjugates and methods of use
SG10201810481UA (en) * 2013-04-29 2018-12-28 Hoffmann La Roche Fcrn-binding abolished anti-igf-1r antibodies and their use in the treatment of vascular eye diseases
EP3628685A1 (fr) * 2013-04-29 2020-04-01 F. Hoffmann-La Roche AG Anticorps modifiés liés au récepteur fcrn humain et procédés d'utilisation
CA2926586C (fr) * 2013-10-11 2020-04-07 Mersana Therapeutics, Inc. Echafaudage polymere fonde sur le phf pour la liberation de medicaments a cible definie
JOP20160154B1 (ar) * 2015-07-31 2021-08-17 Regeneron Pharma أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
WO2017027325A1 (fr) * 2015-08-07 2017-02-16 Imaginab, Inc. Constructions de liaison d'antigène se liant à des molécules cibles
US11485792B2 (en) * 2016-06-06 2022-11-01 Polytherics Limited Antibodies, uses thereof and conjugates thereof
GB201614162D0 (en) * 2016-08-18 2016-10-05 Polytherics Ltd Antibodies, uses thereof and conjugates thereof

Also Published As

Publication number Publication date
CN114555641A (zh) 2022-05-27
MX2021015669A (es) 2022-04-18
EP3994177A1 (fr) 2022-05-11
AU2020299025A1 (en) 2022-01-20
WO2021000018A1 (fr) 2021-01-07
BR112021026663A2 (pt) 2022-04-12
US20220323619A1 (en) 2022-10-13
JP2025069166A (ja) 2025-04-30
KR20220057517A (ko) 2022-05-09
CA3141471A1 (fr) 2021-01-07
EP3994177A4 (fr) 2023-09-20
JP2022540385A (ja) 2022-09-15
IL289523A (en) 2022-03-01
JP7678769B2 (ja) 2025-05-16
CL2021003563A1 (es) 2022-11-18

Similar Documents

Publication Publication Date Title
MA56469A (fr) Anticorps de liaison à psma avec une affinité réduite pour le récepteur fc néonatal
MA56467A (fr) Anticorps dirigés contre caix avec une affinité réduite pour le récepteur fc néonatal
EP3470430A4 (fr) Anticorps de liaison au récepteur de l'interleukine 4
EP3923933A4 (fr) Agonistes du récepteur de l'orexine de type pyrrolidine
EP3600018A4 (fr) Détermination de l'emplacement d'une artère à l'aide d'une détection basée sur une caméra
IL276459A (en) Variable regions of an antibody that targets the NKG2D receptor
EP3665195A4 (fr) Variants d'anticorps fc modifiés pour demi-vie sérique améliorée
WO2017123650A3 (fr) Protéines de fusion se liant à gitr multivalentes et multispécifiques
MA55688A (fr) Réglage de la temporisation de harq pour pdsch avec indicateur de temporisation pdsch à harq en attente
MA49990A (fr) Récepteurs de liaison à l'antigène améliorés
EP3849610A4 (fr) Anticorps anti-récepteur d'il4 à usage vétérinaire
MA52182A (fr) Molécules de liaison à l'antigène ciblant her2 comprenant 4-1bbl
EP3645044A4 (fr) Utilisation d'anticorps dirigés contre une famille à similarité de séquence 19, membre a5, pour le traitement du glaucome
EP3498996A4 (fr) Structure d'échappement pour véhicule à selle
EP3826783A4 (fr) Liaison destinée à différentes structures coulissant ensemble
MA43049A (fr) Anticorps de liaison à un récepteur cannabinoïde 1 humain (cb1)
EP3778362A4 (fr) Structure d'unité de borne usb pour véhicule de type à selle
EP3452289A4 (fr) Détermination d'une séquence de liaison automatique pour liaison optique
EP4010470A4 (fr) Protéine de fusion pour le remodelage de la glycoforme d'anticorps
EP3978527A4 (fr) Anticorps présentant une affinité de liaison améliorée pour le récepteur de l'endothéline a
EP3858722A4 (fr) Véhicule à selle
EP3778363A4 (fr) Structure d'unité de borne usb pour véhicule de type à selle
EP3969902A4 (fr) Biocapteur à récepteur d'éthylène
EP4051714A4 (fr) Anticorps pour liaison à la plasmine
EP3960597A4 (fr) Dispositif de levage/d'abaissement de selle